Intelgenx Technologies Corp
Change company Symbol lookup
Select an option...
IGXT Intelgenx Technologies Corp
DGX Quest Diagnostics Inc
MDLZ Mondelez International Inc
FE FirstEnergy Corp
CADE Cadence Bancorp
SCHD Schwab U.S. Dividend Equity ETF™
ARKK ARK Innovation ETF
URANF International Prospect Ventures Ltd
QSR Restaurant Brands International Inc
STAF Staffing 360 Solutions Inc
Go

Health Care : Pharmaceuticals | Small Cap Growth
Based in Canada
Company profile

IntelGenx Technologies Corp is a Canada-based drug delivery company focused on the development of oral immediate-release and controlled-release products and on developing pharmaceutical products based on its drug delivery technologies. Its product development efforts are based upon over three delivery platform technologies, such as VersaFilm, an oral film technology; VersaTab, a multilayer tablet technology, and AdVersa, a mucoadhesive tablet technology. The VersaFilm technology consists of a thin (25 to 35 micron) polymeric film consisting of the United States Pharmacopeia (USP) components for use in food, pharmaceutical and cosmetic products. Its Multilayer Tablet platform technology allows for the development of oral controlled-release products. Its product portfolio includes INT0001/2004, INT0004/2006, INT0007/2006, INT0008/2007, INT0010/2006, INT0027/2011, INT0030/2011, INT0036/2013, INT0037/2013, INT0039/2013, INT0040/2014, INT0041/2015, INT0042/2015 and INT0043/2015.

Closing Price
$0.46
Day's Change
0.0196 (4.45%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.50
Day's Low
0.431
Volume
(Above Average)
Volume:
378,286

10-day average volume:
355,223
378,286

UPDATE: Bionano Genomics prices offering of 29 million shares at discount of $3.05 a share

9:16 am ET January 8, 2021 (MarketWatch)
Print

Bionano Genomics Inc. (BNGO) said Friday it has priced an underwritten public offering of 29 million shares at $3.05 a share. The stock closed Thursday at $5.00. The genome analysis company has granted the underwriters -- Oppenheimer & Co., which is sole bookrunner, while BTIG acted as lead manager and Ladenburg Thalman and Maxim Group acted as co-managers -- a 30-day option to acquire an additional 4.3 million shares at the offering price. The stock, which has been volatile in recent sessions, slid 18% premarket, but is up more than 300% in the last 12 months, while the SPDR S&P Biotech ETF (XBI) has gained 58% and the S&P 500 has gained 17.5%.

-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com

	

(END) Dow Jones Newswires

January 08, 2021 09:16 ET (14:16 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2021. All rights reserved.